Certificate of Analysis (COA) View the laboratory certificate for this product [ View COA ]

HD Labs Tirzepatide 60mg Vial

R 2,900.00 R 2,600.00
Add to WishlistCompare

HD Labs Tirzepatide 60mg

HD Labs Tirzepatide 60mg is a research-grade peptide reference material featuring tirzepatide, a synthetic peptide studied for its activity at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor.

The product shown is labelled as 60mg per vial and is presented by HD Labs as a peptide research product.

Research Overview

Tirzepatide is notable within peptide research because it interacts with two incretin-related receptor pathways rather than targeting GLP-1 alone. FDA clinical pharmacology information describes tirzepatide as a GIP and GLP-1 receptor agonist and reports effects involving appetite regulation, insulin secretion, glucagon secretion and gastric emptying. Access Data

This dual-receptor activity has made tirzepatide an important subject of ongoing research involving:

  • GIP receptor signalling
  • GLP-1 receptor signalling
  • Metabolic regulation
  • Glucose-dependent insulin secretion
  • Glucagon regulation
  • Appetite and energy-intake pathways
  • Gastric-emptying research
  • Body-composition and metabolic research
Key Features

Dual GIP / GLP-1 Activity

Tirzepatide is characterised by activity at both GIP and GLP-1 receptors.

Metabolic Signalling

Research has examined its effects on glucose-dependent insulin secretion, glucagon regulation and insulin sensitivity.

Appetite & Energy Intake Research

GLP-1 and GIP signalling are involved in pathways associated with appetite and caloric intake, making tirzepatide an important compound for metabolic research.

Peptide Engineering

Tirzepatide incorporates a fatty-diacid component that facilitates albumin binding and extends its pharmacological half-life.

Dosage & Usage

For a 1 mL / 100-unit insulin syringe, it lists:

  • 2.5 mg = 8 units
  • 5 mg = 16 units
  • 7.5 mg = 25 units
  • 10 mg = 33 units
  • 12.5 mg = 42 units
  • 15 mg = 50 units
FAQ's & Tips

What is Tirzepatide?

Tirzepatide is a synthetic peptide that acts at both the GIP and GLP-1 receptors. It has become an important compound in metabolic and incretin-pathway research.

What does GIP/GLP-1 mean?

GIP stands for glucose-dependent insulinotropic polypeptide, while GLP-1 stands for glucagon-like peptide-1. Tirzepatide is designed to interact with both receptor systems.

What is the strength of this HD Labs product?

The product shown is labelled 60mg per vial.

What research areas involve Tirzepatide?

Research involving tirzepatide includes incretin signalling, glucose regulation, appetite pathways, metabolic physiology, peptide pharmacology and receptor biology.

Is this the same as commercially approved tirzepatide medicines?

The active peptide tirzepatide is the subject of approved medicines, but a research product should not automatically be considered equivalent to a registered pharmaceutical product. Pharmaceutical products are manufactured and regulated under specific medicinal-product standards.

Does Tirzepatide target GLP-1 only?

No. Tirzepatide is characterised by activity at both GIP and GLP-1 receptors, which is a defining feature of its pharmacology.

What is the purpose of this product on Health-Tech?

This listing is structured around research reference and laboratory applications, rather than prescribing or treatment guidance.

Research

Research Reference

Tirzepatide provides an interesting model for studying the interaction between GIP and GLP-1 receptor pathways and their relationship with metabolic signalling.

Its molecular design also incorporates a lipid component that supports albumin binding and contributes to its prolonged pharmacokinetic profile.

Research Reference & Study Protocol Notes:
Researchers should consult appropriate primary literature, institutional protocols, analytical documentation and applicable laboratory procedures when designing studies involving tirzepatide.

Reviews